Burlingame, California based mobile platform company Fanfare Entertainment has partnered with Muses Labs to help develop, optimize, and market a next-generation personalized combination therapy for treatment and prevention of Alzheimer’s disease. The MEND (metabolic enhancement for neurodegeneration) Protocol is designed to enable Alzheimer’s disease patients, their caregivers, family members, and…
News
A new drug developed at Lancaster University in the United Kingdom that might help to prevent early stages of Alzheimer’s disease and is about to enter clinical trials. The number of individuals affected by dementia is constantly increasing. According to estimates, there are 850,000 cases in the United Kingdom currently, with estimates that the number…
In a recent study published in the open access Nature Publishing Group journal Scientific Reports, Sussex Neuroscience researchers found a direct association between the main culprit of Alzheimer’s disease and memory loss. Alzheimer’s disease is caused by the formation and accumulation of amyloid plaques in…
Investigators at the Blancette Rockefeller Neurosciences Institute (BRNI) recently discovered that the most significant genetic risk factor associated with Alzheimer’s disease, the Apolipoprotein E4 (ApoE4) gene, leads to a decrease in brain synapses, which occurs frequently prior to the onset of amyloid plaques or tangles developing in Alzheimer’s patients. This discovery may alter the…
Actor Omar Sharif, who became known for his role as Sherif Ali in the movie “Lawrence of Arabia” in 1962, has been diagnosed with Alzheimer’s disease. The announcement was made by the actor’s son, Tarek Sharif, in an interview with the Spanish newspaper El Mundo. The diagnosis was later confirmed by…
A team of researchers at VIB, KU Leuven and Janssen Pharmaceutica found that the presence of insoluble Tau protein aggregates, a typical characteristic of the brain in patients with Alzheimer’s disease, is facilitated by synaptic connections between brain cells. These findings offer the potential for the development of…
Aphios Corporation recently announced that United States Patent 9,034,347 has been granted to the company’s lead compound to treat neurodegenerative diseases like Alzheimer’s disease, Parkinson’s disease, Hutchinson Disease and Down’s syndrome. Alzheimer’s disease, Parkinson’s disease, Hutchinson’s Disease, Kuru Creutzfeldt-Jakob disease, further spongiform encephalopathies and all neurodegenerative diseases in general remain enormous health problems with numerous…
Findings from a recent study published in the journal Neurology revealed that individuals with more skilled jobs may live longer after developing frontotemporal dementia in comparison with individuals with less skilled jobs. Frontotemporal dementia is a condition that mainly affects individuals aged under 65 years and causes…
Findings from a recent study conducted by a team of researchers in China indicate that certain conditions of exposure of extremely low frequency electromagnetic fields could delay the development of Alzheimer’s’ Disease (AD) in rats. The study was published in the journal PLOS One. Extremely low frequency…
The existence of specific and reliable biomarkers for Alzheimer’s disease are crucial to identifying individuals to enroll in clinical trials so that drugs can be tested and diseases can be detected as soon as possible. Facilitating clinical trial enrollment allows studies that are researching and developing therapies that stop or slow Alzheimer’s disease progression…
Recent Posts
- Study reports Alzheimer’s treatment gains in long-term care July 6, 2026
- Awareness month event has new name: Do What You Love to End Alzheimer’s June 1, 2026
- FDA approves Auvelity to treat Alzheimer’s-related agitation May 4, 2026
- Daily Alzheimer’s pill slows brain shrinkage, boosts cognition April 6, 2026
- Researchers explore surgical treatment’s potential in Alzheimer’s March 2, 2026